US20230414698A1 - Collagen 7 compositions and methods of using the same - Google Patents
Collagen 7 compositions and methods of using the same Download PDFInfo
- Publication number
- US20230414698A1 US20230414698A1 US18/169,368 US202318169368A US2023414698A1 US 20230414698 A1 US20230414698 A1 US 20230414698A1 US 202318169368 A US202318169368 A US 202318169368A US 2023414698 A1 US2023414698 A1 US 2023414698A1
- Authority
- US
- United States
- Prior art keywords
- composition
- subject
- need
- arginine
- polysorbate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 101
- 108010035532 Collagen Proteins 0.000 title claims abstract description 30
- 102000008186 Collagen Human genes 0.000 title claims abstract description 30
- 229920001436 collagen Polymers 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 title claims abstract description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 48
- 238000009472 formulation Methods 0.000 claims description 38
- 239000011780 sodium chloride Substances 0.000 claims description 25
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 24
- 229930006000 Sucrose Natural products 0.000 claims description 24
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 24
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 24
- 229940068977 polysorbate 20 Drugs 0.000 claims description 24
- 239000005720 sucrose Substances 0.000 claims description 24
- 239000004475 Arginine Substances 0.000 claims description 23
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 23
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 23
- 208000010975 Dystrophic epidermolysis bullosa Diseases 0.000 claims description 21
- 208000004298 epidermolysis bullosa dystrophica Diseases 0.000 claims description 21
- 239000001488 sodium phosphate Substances 0.000 claims description 18
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 18
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 18
- 239000001509 sodium citrate Substances 0.000 claims description 15
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 15
- 210000003491 skin Anatomy 0.000 claims description 9
- 210000004207 dermis Anatomy 0.000 claims description 8
- 238000001990 intravenous administration Methods 0.000 claims description 7
- 210000002615 epidermis Anatomy 0.000 claims description 5
- 238000001802 infusion Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 235000002639 sodium chloride Nutrition 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 23
- 235000009697 arginine Nutrition 0.000 description 20
- 239000002953 phosphate buffered saline Substances 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 239000000872 buffer Substances 0.000 description 15
- 238000003860 storage Methods 0.000 description 15
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 13
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 11
- 239000004094 surface-active agent Substances 0.000 description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical group [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 9
- 239000011575 calcium Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 229930064664 L-arginine Natural products 0.000 description 8
- 235000014852 L-arginine Nutrition 0.000 description 8
- 238000004873 anchoring Methods 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 6
- 239000000539 dimer Substances 0.000 description 6
- 229940126534 drug product Drugs 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000002738 chelating agent Substances 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 4
- 102000016359 Fibronectins Human genes 0.000 description 4
- 108010067306 Fibronectins Proteins 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 210000002469 basement membrane Anatomy 0.000 description 4
- 239000002577 cryoprotective agent Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 229940088679 drug related substance Drugs 0.000 description 4
- 239000003797 essential amino acid Substances 0.000 description 4
- -1 homotrimers Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 229950008882 polysorbate Drugs 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 239000013628 high molecular weight specie Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 101100496574 Mus musculus Col7a1 gene Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000013627 low molecular weight specie Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000008935 histological improvement Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 150000002840 non-reducing disaccharides Chemical class 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000010494 opalescence Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920005644 polyethylene terephthalate glycol copolymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000008646 thermal stress Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000013060 ultrafiltration and diafiltration Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000012905 visible particle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4993—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Definitions
- the collagen VII (C7) protein is a structural protein in which C7 is both a structural and functional precursor for the formation of anchoring fibrils which enable the attachment of the epidermis and the dermis.
- the C7 monomer assembles as a homotrimer of approximately 900 kDa, containing one NC-1 and one NC-2 binding region. The homotrimer is held together via an alpha helical coil. From a homotrimer, these C7 protein precursors align into an anti-parallel dimer with an increase in molecular weight to 1.8 mDa. Lateral assembly of anti-parallel dimers leads to the formation of the anchoring fibrils.
- the rC7 protein demonstrates “stickiness,” and the propensity to precipitate at higher protein concentrations, particularly in PBS buffer.
- Dystrophic epidermolysis bullosa is a form of EB characterized by development of scarring with healing. (3) In patients with DEB, blistering can be triggered by even minor mechanical trauma owing to the extremely fragile nature of the skin. This leads to a chronic cycle of blistering, healing, and reblistering that causes patients to suffer from painful wounds and debilitating scarring of epithelial tissue. There is no cure for DEB and management focuses on supportive care.
- compositions comprising collagen 7 and methods of preparing such compositions.
- the composition comprises recombinant collagen 7, sodium phosphate, sodium citrate, sodium chloride, arginine, a sugar, and a surfactant. It is possible to exclude one or more of the sodium phosphate, sodium citrate, sodium chloride, arginine, sugar, or surfactant from the composition.
- the sugar is sucrose.
- the surfactant is a polysorbate, such as polysorbate 20 or polysorbate 80.
- the arginine is present in an amount ranging from 200 mM to 5 mM, 150 mM to 50 mM, 100 mM to 75 mM, or about 100 mM.
- the composition comprises recombinant collagen 7, 25 mM to 5 mM sodium phosphate, 25 mM to 1 mM sodium citrate, 100 mM to 20 mM sodium chloride, 150 mM to 50 mM arginine, 75 mM to 35 mM sucrose, and 0.5% to 0.05% polysorbate 20 (w/v) and optionally a pH of 7.2 to 7.1.
- the composition comprises recombinant collagen 7, 10 mM sodium phosphate, 5 mM sodium citrate, 70 mM sodium chloride, 100 mM arginine, 50 mM sucrose, and 0.05% polysorbate 20 (w/v) and has a pH of 7.1.
- the composition comprises recombinant collagen 7, 10 mM sodium phosphate, 5 mM sodium citrate, 70 mM sodium chloride, 100 mM arginine, 50 mM sucrose, and 0.05% polysorbate 20 (w/v) and has a pH of 7.2 ⁇ 0.3.
- the collagen 7 compositions have increased stability.
- the composition is stable for 3 months following storage at ⁇ 65 ⁇ 5° C. or ⁇ 20 ⁇ 5° C. in a 1 liter polycarbonate bottle (500 mL of the composition).
- the composition is stable for 6 months following storage at ⁇ 65 ⁇ 5° C. or ⁇ 20 ⁇ 5° C. in a 10 cc glass vial (5.5 mL of composition).
- the composition is stable following storage for 2 weeks at 25 ⁇ 3° C.
- the composition is stable following storage for up to 1 month at 5 ⁇ 3° C.
- compositions may be pharmaceutical compositions comprising one or more additional pharmaceutical excipients that can be used, for example, to treat DEB.
- Another aspect is directed to a method of treating DEB, the method comprising administering to a subject in need thereof an effective amount of a recombinant collagen 7 composition, as described herein.
- FIG. 1 shows representative immunofluorescent images in tongue and front leg from Col7a1 ⁇ / ⁇ mice surviving 5-7 days following administration of rC7 compositions or a control.
- FIG. 2 shows representative H&E staining in tongue from Col7a1 ⁇ / ⁇ mice following administration of rC7 compositions or a control.
- FIG. 3 is a Kaplan-Meier Curve showing the probability of survival of Col7a1 ⁇ / ⁇ mice following administration of rC7 compositions or a control.
- FIG. 4 shows SEC-HPLC profiles of a rC7 formulation after exposure to freeze/thaw stress.
- FIG. 5 shows SEC-HPLC for 0.5 mg/mL rC7 diluted in D-PBS and 10% serum after incubation for 1 hour at 37° C.
- FIG. 6 shows % HMW species of rC7 formulations containing different amounts of arginine after storage at various temperatures.
- FIG. 7 shows fibronectin binding of rC7 formulations containing different amounts of arginine after storage at various temperatures.
- Anchoring fibrils are structural elements that serve as attachment complexes at the interface between the epithelial and mesenchymal layers of several tissues, including the skin, oral mucosa, and cervix (Chung et al. Dermatol Clin 28(1): 93-105 (2010)). In the skin, anchoring fibrils extend from the lower portion of the epidermal basement membrane to the underlying papillary dermis, securing the association between the epidermal basement membrane and the papillary dermis (Varki et al. J Med Genet 44:181-192 (2007)).
- Collagen 7 produced by recombinant methods described herein may be recovered from the host cell culture system according to standard protocols known in the art (e.g., precipitation, centrifugation, etc.). Recombinant collagen 7 described herein may be secreted into the host cell medium and recovered by ammonium sulfate precipitation and subsequent centrifugation; as demonstrated in the following reference, (Chen et al. J Bio Chem 277(18): 2118-2124 (2002)).
- Collagen 7 produced and recovered by recombinant and molecular biology methods described herein may be purified according to standard protocols known in the art (e.g., dialysis, ion exchange chromatography, affinity chromatography, SDS gel electrophoresis, etc.).
- the recombinant collagen 7 described herein may be purified to homogeneity by ion exchange chromatography; as demonstrated in the following reference, (Chen et al. J Bio. Chem. 277(18): 2118-2124 (2002)).
- rC7 recombinant C7
- a buffer containing a non-essential amino acid, a cryoprotectant, a surfactant, and a chelating agent.
- the non-essential amino acid is arginine, preferably L-arginine.
- the cryoprotectant is a sugar.
- the buffer comprises a phosphate buffer, such as sodium phosphate.
- the chelating agent is citrate.
- the rC7 formulation comprises 10 mM sodium phosphate, sodium citrate, 100 mM L-arginine, 50 mM sucrose, 70 mM NaCl, 0.05% (w/v) polysorbate-20, and pH of about 7.2.
- the rC7 compositions described herein are stable for 3 months at both ⁇ 65 ⁇ 5° C. and ⁇ 20 ⁇ 5° C. In certain embodiments, the rC7 compositions described herein are stable for 6 months at both ⁇ 65 ⁇ 5° C. and ⁇ 20 ⁇ 5° C. In certain embodiments, the rC7 composition is stable for 2 weeks at 25 ⁇ 3° C. and up to 1 month at 5 ⁇ 3° C.
- the rC7 composition described herein is stable for up to 8 hours at 25 ⁇ 3° C. when stored in disposable syringes or for up to 6 hours at 25 ⁇ 3° C. when diluted down to 0.1 mg/mL into saline.
- “stable” means that after the indicated storage conditions, there is no significant difference in the amount of protein, as measured by absorbance at 280 nm, no significant difference in the amount of high molecular weight species, dimers, homotrimers, and low molecular weight species as measured by SEC-HPLC, and no significant loss in potency, as measured in a fibronectin binding assay.
- Sugars that may be used in the compositions include, but are not limited, to non-reducing disaccharides (e.g., sucrose, trehalose) or a sugar alcohol, such as sorbitol.
- the sugar in the composition is sucrose.
- the composition may also include one or more buffers, such as a phosphate buffer (e.g., sodium phosphate, a histidine buffer, a Tris(hydroxymethyl)aminomethane buffer.
- a phosphate buffer e.g., sodium phosphate, a histidine buffer, a Tris(hydroxymethyl)aminomethane buffer.
- the composition may also include one or more surfactants and/or bulking agents.
- Surfactants include but are not limited poloxamers (e.g., Pluronic®), polysorbates (e.g., polysorbate 80, polysorbate 20), CTAB (hexadecyltrimethylammonium bromide), or SDS (sodium dodecyl sulfate or sodium lauryl sulfate).
- the surfactant in the composition is a polysorbate (e.g., polysorbate 20).
- Bulking agents include but are not limited to PVP, PEG, dextran, mannitol and glycine.
- composition may also include one more additional pharmaceutically acceptable excipients.
- pharmaceutically acceptable excipients include, but are not limited to salts, proteins (e.g., albumin), chelating agents (e.g., citrate, EDTA), gelling polymers, urea (or its derivatives), and combinations thereof.
- L-arginine and sucrose and preferably 75-100 mM L-arginine and 1.7% (w/v) sucrose, improved solubility.
- a surfactant e.g., 0.05% polysorbate-20
- NaCl and preferably about 70 mM NaCl, in the formulation improved the appearance.
- the Phase I formulation was also subjected to freezing and thawing stress conditions. using a robust, small scale freeze/thaw model.
- the Phase I formulation was exposed to three freeze/thaw cycles (see Table 2) to reflect freeze/thaw stress that may be encountered at manufacturing scale (scalability).
- the arginine-containing formulations were subjected to 2 months of storage at temperatures of ⁇ 6S° C., ⁇ 20° C., S ⁇ 3° C., and 2S° C. There were no changes in appearance after 2 months at any storage condition.
- the same materials showed no significant change in protein concentration (A280 nm) or SEC-HPLC profile (see Table 4) with the exception of the formulations stored either at 5 ⁇ 3° C. (minimally) or 25° C. After 2 months storage at 25° C., an increase ( ⁇ 2%) in high molecular weight (HMW) species was seen.
- rC7 It is difficult to know what happens when rC7 is injected IV into the bloodstream It is possible, however, to assess the potential for product quality changes by monitoring for any changes when the protein is exposed to more physiologically relevant conditions such as buffers containing 10% bovine serum and held at 37° C.
- the rC7 protein is prone to soluble aggregation and precipitation. These events can be monitored through common analytical techniques.
- the A280 absorbance is used to monitor for changes in protein content.
- the A320 absorbance is used to monitor for changes in turbidity due to insoluble particulate formation.
- D-PBS Dulbecco's phosphate buffered saline
- the SEC-HPLC profiles confirmed that after 1 hour exposure to the various test buffer matrices at 37° C., there were no increases in insoluble aggregates.
- FIG. 5 The exposure to the various buffers triggers an initial change in the lower molecular weight region of the peak, likely due to an increase in the flexibility of the ⁇ -helix.
- Recombinant human collagen 7 was produced in CHO cells.
- rC7 was purified from the CHO cells using two different manufacturing processes.
- a rC7 lot produced from each manufacturing process was formulated in a composition comprising 10 mM sodium phosphate, 5 mM sodium citrate, 70 mM sodium chloride, 100 mM arginine, 50 mM sucrose, 0.05% polysorbate 20, and pH of about 7.1.
- test article 1 and test article 2 were administered intravenously at a dosage of 0.4 mg/mL (16 ⁇ g in 40 ⁇ L) to 26 neonatal Col7a1 ⁇ / ⁇ mice.
- the compositions were administered as a single IV bolus via the superficial temporal vein on postnatal day 2-3.
- a control composition comprising 10 mM sodium phosphate, 5 mM sodium citrate, 70 mM sodium chloride, 100 mM arginine, 50 mM sucrose, 0.05% polysorbate 20, and pH of about 7.1-but without rC7 was also intravenously administered to neonatal Col7a1 ⁇ / ⁇ mice.
- test article 1 and test article 2 resulted in the distribution of rC7 to the dermal-epidermal BMZ in tongue and front leg skin in the neonatal Col7a1 ⁇ / ⁇ mice.
- FIG. 1 In contrast, C7 was not detected in any mouse injected with vehicle control.
- FIG. 1 In contrast, C7 was not detected in any mouse injected with vehicle control.
- Intravenous administration of the test compositions resulted in correction of dermal-epidermal separation in Col7a1 ⁇ / ⁇ mice compared to vehicle control, as demonstrated by representative hematoxylin and eosin (H&E) images of tongue tissue sections.
- FIG. 2 The tongue is the optimal tissue to examine dermal-epidermal separation due to the lack of hair, which can serve to anchor the epidermis to the dermis and prevent the formation of newly induced blisters.
- mice with complete closure i.e., no separation
- the proportion of mice with complete closure was 50% (12 out of 26), 63% (15 out of 26), and 10% (1 out of 10) for Col7a1 ⁇ / ⁇ mice administered test article 1, test article 2, and vehicle control, respectively.
- test article 1 or 2 A single IV administration of test article 1 or 2 to neonatal Col7a1 ⁇ / ⁇ mice resulted in a statistically significant improvement in survival compared to vehicle controls, as shown in Table 7 below and FIG. 3 .
- the median (interquartile-range) survival time was 2.5, 9, and 14 days for Col7a1 ⁇ / ⁇ mice administered vehicle control, test article 1, and test article 2, respectively.
- Drug Substance Frozen liquid with 500 mL fill in 1 L polycarbonate (PC) bottle with rC7 at 1.0 mg/mL
- Drug Product DP—Frozen liquid with 5.5 mL fill in 10 cc glass vial with rC7 at 1.0 mg/mL.
- the formulation comprises 10 mM sodium phosphate, 5 mM sodium citrate, 100 mM L-arginine, 50 mM sucrose, 70 mM NaCl, 0.05% (w/v) polysorbate-20, pH of about 7.2.
- GMP material is stable for 3 months at both ⁇ 65 ⁇ 5° C. and ⁇ 20 ⁇ 5° C., with no significant change in the protein concentration, as measured by absorbance at 280 nm, no significant change in the amount of high molecular weight species, dimers, homotrimers, and low molecular weight species as measured by SEC-HPLC, and no significant change in potency, as measured in a fibronectin binding assay.
- development lots are stable for 6 months at both ⁇ 65 ⁇ 5° C. and ⁇ 20 ⁇ 5° C.
- the formulation is stable for 2 weeks at 25 ⁇ 3° C. and up to 1 month at 5 ⁇ 3° C.
- the formulation is stable for up to 8 hours at 25 ⁇ 3° C. when stored in disposable syringes or for up to 6 hours at 25 ⁇ 3° C. when rC7 is diluted down to 0.1 mg/mL into saline. Furthermore, no changes in protein content were observed in the presence of PBS containing 10% bovine serum after storage for 1 hour at 37° C. This indicates physiological compatibility of the drug product upon administration.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Cosmetics (AREA)
Abstract
Description
- This application is a Continuation application of U.S. patent application Ser. No. 16/875,223 filed May 15, 2020, which is a Continuation application of U.S. patent application Ser. No. 16/065,512 filed Jun. 22, 2018, which is a U.S. National Phase entry application of PCT Patent Application No.: PCT/US2016/067995 filed Dec. 21, 2016, which claims the benefit of, and relies on the filing date of, U.S. provisional patent application No. 62/387,241, filed Dec. 23, 2015; U.S. provisional patent application No. 62/278,816, filed Jan. 14, 2016; and U.S. provisional patent application No. 62/293,209, filed Feb. 9, 2016; the contents of each of which are incorporated herein by reference in their entirety.
- The present invention relates to compositions (e.g., pharmaceutical compositions) and more particularly, to collagen 7 compositions and methods of using the same to treat dystrophic epidermolysis bullosa.
- The collagen VII (C7) protein is a structural protein in which C7 is both a structural and functional precursor for the formation of anchoring fibrils which enable the attachment of the epidermis and the dermis. The C7 monomer assembles as a homotrimer of approximately 900 kDa, containing one NC-1 and one NC-2 binding region. The homotrimer is held together via an alpha helical coil. From a homotrimer, these C7 protein precursors align into an anti-parallel dimer with an increase in molecular weight to 1.8 mDa. Lateral assembly of anti-parallel dimers leads to the formation of the anchoring fibrils. The rC7 protein demonstrates “stickiness,” and the propensity to precipitate at higher protein concentrations, particularly in PBS buffer.
- Lack of C7 leads to abnormal decrease in these anchoring fibrils and a condition known as Dystrophic Epidermolysis Bullosa (DEB). EB encompasses a group of molecularly diverse diseases characterized by the development of blisters after minor mechanical trauma to the skin. (1) Severity, extracutaneous manifestations and clinical course depend on the type of EB; however, almost all patients experience blistering or ruptured skin. (2)
- Dystrophic epidermolysis bullosa (DEB) is a form of EB characterized by development of scarring with healing. (3) In patients with DEB, blistering can be triggered by even minor mechanical trauma owing to the extremely fragile nature of the skin. This leads to a chronic cycle of blistering, healing, and reblistering that causes patients to suffer from painful wounds and debilitating scarring of epithelial tissue. There is no cure for DEB and management focuses on supportive care.
- Dystrophic EB is caused by mutations in the Col7a1 gene, which encodes the alpha chain of collagen VII (C7), a protein essential for the formation of the anchoring fibrils that anchor the basement membrane to the underlying dermis. (4) The condition is inherited as either a dominant form (DDEB) or a recessive form (RDEB), with RDEB typically having a more severe phenotype. (5)
- The DEB mouse model (Col7a1−/−) has a targeted inactivation of the Col7a1 gene, resulting in severe blistering that mimics the histological and ultrastructural presentation of severe human RDEB. (6) These mice have no detectable collagen VII at the dermal-epidermal basement membrane zone (BMZ), completely lack anchoring fibrils, and are born with extensive cutaneous blisters on their ventral surface and hemorrhagic blisters on their paws and neck, with mortality typically observed within the first week of life.
- The present disclosure relates to compositions comprising collagen 7 and methods of preparing such compositions. In certain embodiments, the composition comprises recombinant collagen 7, sodium phosphate, sodium citrate, sodium chloride, arginine, a sugar, and a surfactant. It is possible to exclude one or more of the sodium phosphate, sodium citrate, sodium chloride, arginine, sugar, or surfactant from the composition.
- In certain embodiments, the sugar is sucrose. In certain embodiments the surfactant is a polysorbate, such as
polysorbate 20 orpolysorbate 80. - In certain embodiments, the sodium phosphate is present in an amount ranging from 100 mM to 1 mM, 50 mM to 5 mM, 25 mM to 5 mM, 10 mM to 5 mM, 10 mM to 1 mM or about 10 mM.
- In certain embodiments, the sodium citrate is present in an amount ranging from 100 mM to 1 mM, 50 mM to 1 mM, 25 mM to 1 mM, 10 mM to 1 mM, 5 mM to 1 mM or about 5 mM.
- In certain embodiments, the sodium chloride is present in an amount ranging from 200 mM to 10 mM, 100 mM to 20 mM, 80 mM to 50 mM, or about 70 mM.
- In certain embodiments, the arginine is present in an amount ranging from 200 mM to 5 mM, 150 mM to 50 mM, 100 mM to 75 mM, or about 100 mM.
- In certain embodiments, the sugar is present in an amount ranging from 100 mM to 10 mM, 100 mM to 50 mM, 75 mM to 35 mM, 60 mM to 40 mM, or about 50 mM. In certain embodiments, the sucrose is present in an amount ranging from 100 mM to 1 mM, 100 mM to 50 mM, 75 mM to 35 mM, 60 mM to 40 mM, or about 50 mM.
- In certain embodiments, the surfactant is present in an amount ranging from 1% to 0.01%, 0.5% to 0.05%, 0.025% to 0.05%, 0.1% to 0.05%, 0.05% to 0.01% or about 0.05% (w/v). In certain embodiments, the polysorbate (e.g., polysorbate 20) is present in an amount ranging from 1% to 0.01%, 0.5% to 0.05%, 0.025% to 0.05%, 0.1% to 0.05%, 0.05% to 0.01% or about 0.05% (w/v).
- In certain embodiments, the composition has a pH of between 8.0 to 6.0, 7.5 to 6.5, 7.5 to 7.0, 7.4 to 7.0, 7.3 to 7.0, 7.2 to 7.0, 7.1 to 7.0, 7.2 to 7.1, 7.2±0.3, about 7.1, or about 7.2.
- In certain embodiments, the composition comprises
recombinant collagen 7, 100 mM to 10 mM sodium phosphate, 100 mM to 1 mM sodium citrate, 200 mM to 10 mM sodium chloride, 200 mM to 10 mM arginine, 100 mM to 10 mM sucrose, and 1.0% to 0.01% (w/v)polysorbate 20 and optionally a pH of 7.2 to 7.1. - In certain embodiments, the composition comprises
recombinant collagen 7, 25 mM to 5 mM sodium phosphate, 25 mM to 1 mM sodium citrate, 100 mM to 20 mM sodium chloride, 150 mM to 50 mM arginine, 75 mM to 35 mM sucrose, and 0.5% to 0.05% polysorbate 20 (w/v) and optionally a pH of 7.2 to 7.1. - In one embodiment, the composition comprises recombinant collagen 7, about 10 mM sodium phosphate, about 5 mM sodium citrate, about 70 mM sodium chloride, about 100 mM arginine, about 50 mM sucrose, and about 0.05% polysorbate 20 (w/v) and has a pH of about 7.1.
- In another embodiment, the composition comprises recombinant collagen 7, 10 mM sodium phosphate, 5 mM sodium citrate, 70 mM sodium chloride, 100 mM arginine, 50 mM sucrose, and 0.05% polysorbate 20 (w/v) and has a pH of 7.1.
- In another embodiment, the composition comprises recombinant collagen 7, 10 mM sodium phosphate, 5 mM sodium citrate, 70 mM sodium chloride, 100 mM arginine, 50 mM sucrose, and 0.05% polysorbate 20 (w/v) and has a pH of 7.2±0.3.
- In certain embodiments, the recombinant collagen 7 is a human collagen 7.
- The collagen 7 compositions have increased stability. In certain embodiments, the composition is stable for 3 months following storage at −65±5° C. or −20±5° C. in a 1 liter polycarbonate bottle (500 mL of the composition). In certain embodiments, the composition is stable for 6 months following storage at −65±5° C. or −20±5° C. in a 10 cc glass vial (5.5 mL of composition). In certain embodiments, the composition is stable following storage for 2 weeks at 25±3° C. In certain embodiments, the composition is stable following storage for up to 1 month at 5±3° C.
- The compositions may be pharmaceutical compositions comprising one or more additional pharmaceutical excipients that can be used, for example, to treat DEB.
- Another aspect is directed to a method of treating DEB, the method comprising administering to a subject in need thereof an effective amount of a recombinant collagen 7 composition, as described herein.
-
FIG. 1 shows representative immunofluorescent images in tongue and front leg from Col7a1−/− mice surviving 5-7 days following administration of rC7 compositions or a control. -
FIG. 2 shows representative H&E staining in tongue from Col7a1−/− mice following administration of rC7 compositions or a control. -
FIG. 3 is a Kaplan-Meier Curve showing the probability of survival of Col7a1−/− mice following administration of rC7 compositions or a control. -
FIG. 4 shows SEC-HPLC profiles of a rC7 formulation after exposure to freeze/thaw stress. -
FIG. 5 shows SEC-HPLC for 0.5 mg/mL rC7 diluted in D-PBS and 10% serum after incubation for 1 hour at 37° C. -
FIG. 6 shows % HMW species of rC7 formulations containing different amounts of arginine after storage at various temperatures. -
FIG. 7 shows fibronectin binding of rC7 formulations containing different amounts of arginine after storage at various temperatures. - The foregoing and other objects, features, and advantages of the rC7 compositions will become more apparent from the following detailed description.
- As a major component of anchoring fibrils, collagen 7 functions in maintaining tissue integrity. Anchoring fibrils are structural elements that serve as attachment complexes at the interface between the epithelial and mesenchymal layers of several tissues, including the skin, oral mucosa, and cervix (Chung et al. Dermatol Clin 28(1): 93-105 (2010)). In the skin, anchoring fibrils extend from the lower portion of the epidermal basement membrane to the underlying papillary dermis, securing the association between the epidermal basement membrane and the papillary dermis (Varki et al. J Med Genet 44:181-192 (2007)). This association aids to provide and maintain cohesion between the epidermis and dermis, contributing to the integrity to the skin, which is critical for its proper structure, function, and homeostasis (Villone et al. J Biol Chem 283(36): 24506-24513 (2008)). Nucleic acid sequences encoding collagen 7 and polypeptides encoding thereby are known in the art. In one embodiment the recombinant collagen 7 is a human collagen 7.
- Collagen 7 produced by recombinant methods described herein may be recovered from the host cell culture system according to standard protocols known in the art (e.g., precipitation, centrifugation, etc.). Recombinant collagen 7 described herein may be secreted into the host cell medium and recovered by ammonium sulfate precipitation and subsequent centrifugation; as demonstrated in the following reference, (Chen et al. J Bio Chem 277(18): 2118-2124 (2002)).
- Collagen 7 produced and recovered by recombinant and molecular biology methods described herein, may be purified according to standard protocols known in the art (e.g., dialysis, ion exchange chromatography, affinity chromatography, SDS gel electrophoresis, etc.). The recombinant collagen 7 described herein may be purified to homogeneity by ion exchange chromatography; as demonstrated in the following reference, (Chen et al. J Bio. Chem. 277(18): 2118-2124 (2002)).
- This disclosure provides a recombinant C7 (rC7) formulation containing a buffer, a non-essential amino acid, a cryoprotectant, a surfactant, and a chelating agent. In certain embodiments the non-essential amino acid is arginine, preferably L-arginine. In certain embodiments, the cryoprotectant is a sugar. In certain embodiments, the buffer comprises a phosphate buffer, such as sodium phosphate. In certain embodiments the chelating agent is citrate. In a preferred embodiment, the rC7 formulation comprises 10 mM sodium phosphate, sodium citrate, 100 mM L-arginine, 50 mM sucrose, 70 mM NaCl, 0.05% (w/v) polysorbate-20, and pH of about 7.2.
- As compared to the previously used PBS buffer, these improved formulations enhance rC7 solubility, increasing rC7 protein concentration about 8-10 fold as compared to previously used PBS buffers, and increase robustness/stability against freeze and thaw, as well as thermal stresses during storage and handling. In certain embodiments, the rC7 compositions described herein are stable for 3 months at both −65±5° C. and −20±5° C. In certain embodiments, the rC7 compositions described herein are stable for 6 months at both −65±5° C. and −20±5° C. In certain embodiments, the rC7 composition is stable for 2 weeks at 25±3° C. and up to 1 month at 5±3° C. In terms of delivery device compatibility, in certain embodiments, the rC7 composition described herein is stable for up to 8 hours at 25±3° C. when stored in disposable syringes or for up to 6 hours at 25±3° C. when diluted down to 0.1 mg/mL into saline. As used herein, “stable” means that after the indicated storage conditions, there is no significant difference in the amount of protein, as measured by absorbance at 280 nm, no significant difference in the amount of high molecular weight species, dimers, homotrimers, and low molecular weight species as measured by SEC-HPLC, and no significant loss in potency, as measured in a fibronectin binding assay.
- Sugars that may be used in the compositions include, but are not limited, to non-reducing disaccharides (e.g., sucrose, trehalose) or a sugar alcohol, such as sorbitol. In certain embodiments, the sugar in the composition is sucrose.
- The composition may also include one or more buffers, such as a phosphate buffer (e.g., sodium phosphate, a histidine buffer, a Tris(hydroxymethyl)aminomethane buffer.
- The composition may also include one or more surfactants and/or bulking agents. Surfactants include but are not limited poloxamers (e.g., Pluronic®), polysorbates (e.g.,
polysorbate 80, polysorbate 20), CTAB (hexadecyltrimethylammonium bromide), or SDS (sodium dodecyl sulfate or sodium lauryl sulfate). In certain embodiments, the surfactant in the composition is a polysorbate (e.g., polysorbate 20). Bulking agents include but are not limited to PVP, PEG, dextran, mannitol and glycine. - The composition may also include one more additional pharmaceutically acceptable excipients. Examples of pharmaceutically acceptable excipients include, but are not limited to salts, proteins (e.g., albumin), chelating agents (e.g., citrate, EDTA), gelling polymers, urea (or its derivatives), and combinations thereof.
- One aspect is directed to the use of the compositions described herein to treat DEB. Also provided is a method of treating DEB comprising administering to a subject in need thereof a composition comprising recombinant collagen 7, a buffer, anon-essential amino acid, a cryoprotectant, a surfactant, and a chelating agent. In certain embodiment, the buffer is a phosphate buffer (e.g., sodium phosphate). In certain embodiments, the non-essential amino acid is arginine. In certain embodiments, the cryoprotectant is a sugar, such as sucrose. In certain embodiments the surfactant is a polysorbate, such as
polysorbate 20 orpolysorbate 80. In certain embodiments, the chelating agent is citrate. The amount of each component can vary as described throughout the application. In one embodiment, the composition comprises recombinant collagen 7, 10 mM sodium phosphate, 5 mM sodium citrate, 70 mM sodium chloride, 100 mM arginine, 50 mM sucrose, and 0.05% polysorbate 20 (w/v) and has a pH of 7.1 or 7.2. - Five formulations were selected to compare freeze/thaw profiles and thermal stability, including the previously used PBS formulation. These formulations are listed in Table 1.
-
TABLE 1 Formulation Buffer Ingredients 1 PBS, pH 7.3 0.5 mg/mL C7, 150 mm NaCl 2 10 mM Phos pH 7.3 0.5 mg/mL C7, 70 mM NaCl, 50 mM Arg, 50 mM Gln; 1.7% sucrose, 0.05% (v/v) Polysorbate-20, 5 mM citrate 3 10 mM Phos pH 7.3 0.5 mg/mL C7, 100 mM NaC1, 50 mM Arg, 1.7% sucrose, 0.05%(v/v) Polysorbate-20, 5 mM citrate 4 10 mM Phos pH 7.3 0.5 mg/mL C7, 0 mM NaCl, 100 mM Arg, 1.7% sucrose, 0.05%(v/v) Polysorbate-20, 5 mM citrate 5 20 mM Histidine 0.5 mg/mL C7, pH 7.3 70 mM NaCl, 50 mM Arg, 1.7% sucrose 0.05%(v/v) Polysorbate-20, 5 mM citrate 6 10 mMTRIS pH 7.3 0.5 mg/mL C7, 70 mM NaCl, 50 mM Arg, 0.05%(v/v) Polysorbate-20, 5 mM citrate - By testing these formulations, it was discovered that L-arginine and sucrose, and preferably 75-100 mM L-arginine and 1.7% (w/v) sucrose, improved solubility. The inclusion of a surfactant (e.g., 0.05% polysorbate-20) improved filterability and is expected to lower potential non-specific adsorption. The inclusion of NaCl, and preferably about 70 mM NaCl, in the formulation improved the appearance.
- The previously used rC7 formulation (PBS) only achieved solubility of upwards of 0.4 mg/mL with significant viscosity challenges above this concentration. In some cases, the PBS formulation could be pushed to upwards of 0.8 mg/mL, but only under very specific lab conditions that were not scalable or compatible with conventional protein purification processes, such as UF/DF. A formulation comprising 1 mg/mL rC7, 10 mM phosphate, 5 mM citrate, 100 mM L-arginine, 1.7% (w/v) sucrose, 70 mM NaCl, 0.05% (v/v) polysorbate-20 at pH of about 7.2 (“Phase I formulation”) was able to achieve approximately ten-fold higher protein concentration (upwards of about 4 mg/mL) using conventional spin columns with a 100 kDa PES molecular weight cutoff.
- Improvements in the viscosity were seen as well when compared to the PBS formulation. The PBS formulation was not able to support protein concentrations above 0.8 mg/mL. Therefore, head-to-head comparisons with higher concentration protein formulations were not possible. However, the viscosity readings for the 3 mg/mL rC7 protein formulations were all around 4 centipoise (cp), which is not considered highly viscous. These data demonstrate that in general, the increase in viscosity correlates to the increase in rC7 protein concentration. If the viscosity is compared to the protein concentration (cP/protein concentration), it becomes evident that the arginine containing formulations have lower values than those in the PBS formulation. Thus, the arginine formulations support higher protein content while better controlling increases in viscosity.
- Under the intensity of a Tyndall light, the refraction of the protein and protein precipitates was significantly less for the Phase I formulation at the higher protein concentrations (upwards of 3-4 mg/mL). This gave the Phase I formulation a clearer and less turbid appearance.
- The Phase I formulation was also subjected to freezing and thawing stress conditions. using a robust, small scale freeze/thaw model. The Phase I formulation was exposed to three freeze/thaw cycles (see Table 2) to reflect freeze/thaw stress that may be encountered at manufacturing scale (scalability).
-
TABLE 2 Freeze/Thaw (F/T) Stress Cycle for 100 mL in PETG Bottles Step Ramp Target T Time 1 Hold 5° C. 30 min 2 Ramp −5° C. 0.2° C./ min 3 Hold −5° C. 6 Hours 4 Ramp −20° C. 0.2° C./min 5 Hold −20° C. 6 Hours 6 Ramp −20° C. 0.2° C./min 7 Hold 25° C. 3 Hours 8 Ramp 5° C. 30 min - After the 3 cycles were completed, there were no changes in either the protein content (as measured by absorbance at A280 nm; see Table 3) or in association state (as measured by SEC-HPLC; see
FIG. 4 ). -
TABLE 3 Changes After Freeze/Thaw Stress A280 nm Size Exclusion Chromatography (SEC-HPLC) mg/mL % HMW % Dimer % Homotrimer % LMW T0 1.0 1.4 10.7 78.7 9.2 Post 31.0 1.8 11.2 78.1 8.9 FIT Cycles - The arginine-containing formulations were subjected to 2 months of storage at temperatures of −6S° C., −20° C., S±3° C., and 2S° C. There were no changes in appearance after 2 months at any storage condition. The same materials showed no significant change in protein concentration (A280 nm) or SEC-HPLC profile (see Table 4) with the exception of the formulations stored either at 5±3° C. (minimally) or 25° C. After 2 months storage at 25° C., an increase (˜2%) in high molecular weight (HMW) species was seen.
-
TABLE 4 Changes After Storage for Two Months at Various Temperatures A280 nm Size Exclusion Chromatography (SEC-HPLC) Sample mg/mL % HMW % Dimer % Homotrimer % LMW T0 <−65° C. 1.1 1.6 9.9 77.3 11.2 −20° C. 1.1 1.7 10.2 76.8 11.4 5° C. 1.1 2.3 12.4 74.4 10.9 25° C. 1.1 4.1 18.0 67.5 10.4 - The Phase I formulation at a 1 mg/mL dose was also assessed for compatibility with the animal delivery devices and dosing syringes. The 1 mg/mL drug product was injected into the infusion set(s) with the appropriate syringe(s), and the drug held for up to 60 minutes in each of the devices. There were no visible particles or pH shifts after 60 minutes in the devices. The SEC-HPLC profiles also demonstrated no significant changes.
- It is difficult to know what happens when rC7 is injected IV into the bloodstream It is possible, however, to assess the potential for product quality changes by monitoring for any changes when the protein is exposed to more physiologically relevant conditions such as buffers containing 10% bovine serum and held at 37° C. The rC7 protein is prone to soluble aggregation and precipitation. These events can be monitored through common analytical techniques. The A280 absorbance is used to monitor for changes in protein content. The A320 absorbance is used to monitor for changes in turbidity due to insoluble particulate formation. SEC-HPLC is used to monitor for changes in the soluble protein where HMW and/or LMW species may form To maximize the impact of the serum effect, the buffers were diluted with equal parts serum and incubated in the presence of rC7 (in the Phase I formulation) at a final protein concentration of 0.5 mg/mL. To simulate body temperature, all samples were held for 1 hour at 37° C. The summary of these results is listed in Table 5. The results demonstrated no changes in protein content (A280), or turbidity (A320), after exposure to physiological media for 1 hour at 37° C. Thus, the data suggest there are no apparent immediate solubility limitations upon dilution of rC7 delivery into serum.
-
TABLE 5 A280 and A320 Absorbance after 1 hour at 37° C. exposure Initial 1 hr at Initial 1 hr at (A280/mm) 37° C. (A320/m) 37° C. Water 0.00145 0.00134 0.00090 0.00097 Placebo in PBS + Ca 0 0.00215 0.00127 0.00138 Placebo in PBS no Ca 0.00375 0.00225 0.00221 0.00108 Placebo in PBS + Ca 0.32405 0.31336 0.01319 0.0131 and 10% serum Placebo in PBS no Ca 0.32068 0.31129 0.01363 0.01267 and 10% serum 0.5 mg/mL C7 in 0.02896 0.03234 0.00188 0.00224 PBS + Ca 0.5 mg/mL C7 in PBS 0.03134 0.03139 0.00210 0.00184 no Ca 0.5 mg/mL C7 in PBS + 0.33182 0.33807 0.01321 0.01345 Ca and 10% serum 0.5 mg/mL C7 in PBS 0.34846 0.33424 0.01386 0.01338 no Ca and 10 % serum 90% PBS + 10% serum n/a 0.31847 n/a 0.01343 - To see if calcium and magnesium had an effect on changes in product quality, the starting Dulbecco's phosphate buffered saline (D-PBS) was obtained without the inclusion of Ca2+ and Mg2+ cations in the buffer. This solution was tested and compared to D-PBS where physiological levels of Ca2+ and Mg2+ were added. These were found to have no effect on the results (Table 5).
- The SEC-HPLC profiles confirmed that after 1 hour exposure to the various test buffer matrices at 37° C., there were no increases in insoluble aggregates.
FIG. 5 . The exposure to the various buffers triggers an initial change in the lower molecular weight region of the peak, likely due to an increase in the flexibility of the α-helix. - Thermal stability studies were conducted on rC7 formulations containing different amounts of L-arginine (25 mM to 100 mM). The results show that lowering the L-arginine level leads to a slight increase in high molecular weight species and decreased potency (as measured by a fibronectin binding assay) after storage for up to one month at both 5±3° C. and 25÷3° C.
FIGS. 6 and 7 . Additionally, more opalescence was seen in the samples at 25 mM and 50 mM arginine. Other excipient levels were kept the same in these studies. - Based on initial development studies, a formulation containing 10 mM sodium phosphate, 5 mM sodium citrate, 70 mM sodium chloride, 100 mM arginine, 50 mM sucrose, 0.05
% polysorbate 20, and pH of about 7.1 was used for administration to Col7a1−/− mice in a mouse model of DEB. - Recombinant human collagen 7 (rC7) was produced in CHO cells. rC7 was purified from the CHO cells using two different manufacturing processes. A rC7 lot produced from each manufacturing process was formulated in a composition comprising 10 mM sodium phosphate, 5 mM sodium citrate, 70 mM sodium chloride, 100 mM arginine, 50 mM sucrose, 0.05
% polysorbate 20, and pH of about 7.1. - The study was conducted in a total of 59 neonatal Col7a1−/− mice across 3 treatment groups to evaluate distribution and histological improvement following a single IV administration of rC7 on postnatal day 2-3. Overall survival was additionally examined in this study. Each composition (
test article 1 and test article 2) was administered intravenously at a dosage of 0.4 mg/mL (16 μg in 40 μL) to 26 neonatal Col7a1−/− mice. The compositions were administered as a single IV bolus via the superficial temporal vein on postnatal day 2-3. A control composition comprising 10 mM sodium phosphate, 5 mM sodium citrate, 70 mM sodium chloride, 100 mM arginine, 50 mM sucrose, 0.05% polysorbate 20, and pH of about 7.1-but without rC7 was also intravenously administered to neonatal Col7a1−/− mice. - Administration of
test article 1 andtest article 2 resulted in the distribution of rC7 to the dermal-epidermal BMZ in tongue and front leg skin in the neonatal Col7a1−/− mice.FIG. 1 . In contrast, C7 was not detected in any mouse injected with vehicle control.FIG. 1 . - Intravenous administration of the test compositions resulted in correction of dermal-epidermal separation in Col7a1−/− mice compared to vehicle control, as demonstrated by representative hematoxylin and eosin (H&E) images of tongue tissue sections.
FIG. 2 . The tongue is the optimal tissue to examine dermal-epidermal separation due to the lack of hair, which can serve to anchor the epidermis to the dermis and prevent the formation of newly induced blisters. - The proportion of mice with complete closure (i.e., no separation) between the epidermis and dermis in tongue was 50% (12 out of 26), 63% (15 out of 26), and 10% (1 out of 10) for Col7a1−/− mice administered
test article 1,test article 2, and vehicle control, respectively. The proportion of Col7a1−/− mice with complete closure of dermal-epidermal separation was higher in rC7 treated mice than vehicle control (test article 1 vs vehicle Fisher p=0.06,test article 2 vs vehicle Fisher p=0.02). The proportion of Col7a1−/− mice with closure of dermal-epidermal separation did not differ between rC7 treated mice (Fisher p=0.58). - A single IV administration of
test article FIG. 3 . The median (interquartile-range) survival time was 2.5, 9, and 14 days for Col7a1−/− mice administered vehicle control,test article 1, andtest article 2, respectively. -
TABLE 6 Hazard Ratios Comparing Treatment Groups Comparison Hazard Ratio 95% Confidence Interval P Value Test Article 1 versus 0.18 0.08-0.40 <0.001 Test Article 2 versus0.11 0.05-0.25 <0.001 Test Article1 versus 1.66 0.87-3.15 0.13 Test Article 2 - In Table 6, hazard ratios were estimated in a Cox proportional hazards model. The proportional hazards assumption was satisfied as assessed by Schoenfeld residuals (p>0.37).
- This study demonstrated efficacy for the tested rC7 compositions in a neonatal murine model of DEB. Specifically, both test articles distributed to the dermal-epidermal BMZ in tongue and skin, corrected dermal-epidermal separation, and resulted in a statistically significant improvement in survival compared to vehicle control following a single IV injection in Col7a1−/− mice.
- To support
Phase 1/11 clinical trials of Dystrophic Epidermolysis Bullosa (DEB) program, the following drug substances/drug products will be used: Drug Substance (DS)—Frozen liquid with 500 mL fill in 1 L polycarbonate (PC) bottle with rC7 at 1.0 mg/mL; Drug Product (DP)—Frozen liquid with 5.5 mL fill in 10 cc glass vial with rC7 at 1.0 mg/mL. The formulation comprises 10 mM sodium phosphate, 5 mM sodium citrate, 100 mM L-arginine, 50 mM sucrose, 70 mM NaCl, 0.05% (w/v) polysorbate-20, pH of about 7.2. - In terms of long-term storage stability, for DS, to date, GMP material is stable for 3 months at both −65±5° C. and −20±5° C., with no significant change in the protein concentration, as measured by absorbance at 280 nm, no significant change in the amount of high molecular weight species, dimers, homotrimers, and low molecular weight species as measured by SEC-HPLC, and no significant change in potency, as measured in a fibronectin binding assay. For DP, to date, development lots are stable for 6 months at both −65±5° C. and −20±5° C. For handling, the formulation is stable for 2 weeks at 25±3° C. and up to 1 month at 5±3° C. Care should be taken to minimize exposure from light, prevent excessive shaking during product handling. In terms of delivery device compatibility, the formulation is stable for up to 8 hours at 25±3° C. when stored in disposable syringes or for up to 6 hours at 25±3° C. when rC7 is diluted down to 0.1 mg/mL into saline. Furthermore, no changes in protein content were observed in the presence of PBS containing 10% bovine serum after storage for 1 hour at 37° C. This indicates physiological compatibility of the drug product upon administration.
- While one or more exemplary embodiments have been described in the specification, it will be understood by those of ordinary skill in the art that various changes in form and details may be made therein without departing from the spirit and scope of the inventive concept as defined by the claims that follow.
-
- 1. Fine J D, Bauer E A, Gedde-Dahl, T (1999). Inherited epidermolysis bullosa: definition and historical overview. In: Fine J D, Bauer E A, McGuire J, Moshell A, eds. Epidermolysisbullosa: Clinical, epidemiologic, and laboratory advances, and the findings of the National Epidermolysis Bullosa Registry. Baltimore: Johns Hopkins University Press; 1999:1-19.
- 2. Fine J D, Eady R A, Bauer E A, et al. The classification of inherited epidermolysis bullosa (E B): Report of the Third International Consensus Meeting on Diagnosis and Classification of E B. J Am Acad Dermatol. 2008 June; 58(6):931-50.
- 3. Bruckner-Tuderman L. Dystrophic epidermolysis bullosa: Pathogenesis and clinical features. Dermatol Clin. 2010 January; 28(1):107-14.
- 4. Pfendner E G, Lucky A W. Dystrophic Epidermolysis Bullosa. 2006 Aug. 21 [Updated 2010 Nov. 4]. In: Pagon R A, Adam M P, Bird T D, et al., editors. Gene Reviews T M [Internet]. Seattle (W A): University of Washington, Seattle; 1993-2013.
- 5. Dang N, Murrell D F. Mutation analysis and characterization of COL7A1 mutations in dystrophic epidermolysis bullosa. Exp Dermatol. 2008 July; 17(7):553-68.
- 6. Heinonen S. Targeted inactivation of the type VII collagen gene (Col7a1) in mice results in severe blistering phenotype: a model for recessive dystrophic epidermolysis bullosa. J Cell Sci. 1999 November; 112(21):3641-8.
Claims (17)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/169,368 US20230414698A1 (en) | 2015-12-23 | 2023-02-15 | Collagen 7 compositions and methods of using the same |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562387241P | 2015-12-23 | 2015-12-23 | |
US201662278816P | 2016-01-14 | 2016-01-14 | |
US201662293209P | 2016-02-09 | 2016-02-09 | |
PCT/US2016/067995 WO2017112757A1 (en) | 2015-12-23 | 2016-12-21 | Collagen 7 compositions and methods of using the same |
US201816065512A | 2018-06-22 | 2018-06-22 | |
US16/875,223 US20200316158A1 (en) | 2015-12-23 | 2020-05-15 | Collagen 7 compositions and methods of using the same |
US18/169,368 US20230414698A1 (en) | 2015-12-23 | 2023-02-15 | Collagen 7 compositions and methods of using the same |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/875,223 Continuation US20200316158A1 (en) | 2015-12-23 | 2020-05-15 | Collagen 7 compositions and methods of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230414698A1 true US20230414698A1 (en) | 2023-12-28 |
Family
ID=59091196
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/065,512 Active US10695395B2 (en) | 2015-12-23 | 2016-12-21 | Collagen 7 compositions and methods of using the same |
US16/875,223 Abandoned US20200316158A1 (en) | 2015-12-23 | 2020-05-15 | Collagen 7 compositions and methods of using the same |
US18/169,368 Pending US20230414698A1 (en) | 2015-12-23 | 2023-02-15 | Collagen 7 compositions and methods of using the same |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/065,512 Active US10695395B2 (en) | 2015-12-23 | 2016-12-21 | Collagen 7 compositions and methods of using the same |
US16/875,223 Abandoned US20200316158A1 (en) | 2015-12-23 | 2020-05-15 | Collagen 7 compositions and methods of using the same |
Country Status (8)
Country | Link |
---|---|
US (3) | US10695395B2 (en) |
EP (1) | EP3394095B1 (en) |
JP (3) | JP6943858B2 (en) |
CN (2) | CN108463470B (en) |
CA (1) | CA3006998A1 (en) |
IL (2) | IL259583B (en) |
MX (1) | MX2018007468A (en) |
WO (1) | WO2017112757A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108463470B (en) * | 2015-12-23 | 2021-10-22 | 菲尼克斯组织修复公司 | Collagen 7 compositions and methods of use thereof |
TWI818166B (en) * | 2019-03-27 | 2023-10-11 | 美商菲尼克斯組織修復公司 | Systems and methods for producing collagen 7 compositions |
EP4415745A1 (en) | 2021-10-12 | 2024-08-21 | Phoenix Tissue Repair, Inc. | Collagen 7 protein replacement therapy |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2757874B1 (en) * | 1996-12-17 | 2003-04-25 | Biocem | RECOMBINANT COLLAGENS AND DERIVED PROTEINS PRODUCED BY PLANTS, THEIR METHODS OF OBTAINING AND THEIR USES |
DE60322513D1 (en) * | 2002-02-27 | 2008-09-11 | Immunex Corp | Stabilized TNFR-Fc formulation with arginine |
GB0216001D0 (en) * | 2002-07-10 | 2002-08-21 | Nat Blood Authority | Process and composition |
US20080287349A1 (en) * | 2003-05-09 | 2008-11-20 | Jeffrey Peterson | Fibroblast growth factor 20 and methods of use thereof |
TR201809670T4 (en) * | 2003-12-19 | 2018-07-23 | Novo Nordisk Healthcare Ag | Stabilized compositions of factor VII polypeptides. |
JP4832107B2 (en) * | 2006-02-23 | 2011-12-07 | ソニーケミカル&インフォメーションデバイス株式会社 | Implementation method |
WO2008063717A2 (en) * | 2006-08-01 | 2008-05-29 | Illumigen Biosciences, Inc. | Pharmaceutical manufacturing methods |
EP2458990B1 (en) * | 2009-07-28 | 2016-03-30 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
US8475824B2 (en) | 2010-01-26 | 2013-07-02 | Warsaw Orthopedic, Inc. | Resorbable matrix having elongated particles |
WO2011113024A1 (en) * | 2010-03-11 | 2011-09-15 | University Of Southern California | Compositions and methods for healing of skin wounds |
US20130237485A1 (en) * | 2010-05-06 | 2013-09-12 | University Of Southern California | Methods and Agents for Enhancing Wound Healing |
BR112013026883A2 (en) * | 2011-04-20 | 2021-12-07 | Sandoz Ag | Pharmaceutical composition, kit comprising a composition and method of producing a pharmaceutical composition |
JP2014532713A (en) * | 2011-11-02 | 2014-12-08 | ハルシオン,インコーポレイテッド | Wound treatment methods and compositions |
US20180104186A1 (en) * | 2013-03-13 | 2018-04-19 | University Of Miami | Methods and compositions for the treatment of epidermolysis bullosa |
CN104740612A (en) * | 2013-12-31 | 2015-07-01 | 上海中信国健药业股份有限公司 | Liquid formulation of receptor antibody fusion protein |
EP3129043A4 (en) * | 2014-04-08 | 2017-11-15 | University of Southern California | Polypeptide compositions with type vii collagen fibronectin type iii- like repeats and treatment methods for wound closure and healing |
CN108463470B (en) * | 2015-12-23 | 2021-10-22 | 菲尼克斯组织修复公司 | Collagen 7 compositions and methods of use thereof |
CN109069592B (en) * | 2016-03-16 | 2023-03-07 | 菲尼克斯组织修复公司 | Method for purifying collagen 7 |
-
2016
- 2016-12-21 CN CN201680075057.5A patent/CN108463470B/en active Active
- 2016-12-21 US US16/065,512 patent/US10695395B2/en active Active
- 2016-12-21 MX MX2018007468A patent/MX2018007468A/en unknown
- 2016-12-21 CN CN202111171969.1A patent/CN114225013A/en active Pending
- 2016-12-21 CA CA3006998A patent/CA3006998A1/en active Pending
- 2016-12-21 WO PCT/US2016/067995 patent/WO2017112757A1/en active Application Filing
- 2016-12-21 JP JP2018533834A patent/JP6943858B2/en active Active
- 2016-12-21 EP EP16880019.1A patent/EP3394095B1/en active Active
-
2018
- 2018-05-24 IL IL259583A patent/IL259583B/en unknown
-
2020
- 2020-05-15 US US16/875,223 patent/US20200316158A1/en not_active Abandoned
-
2021
- 2021-09-09 JP JP2021146575A patent/JP2021185201A/en active Pending
-
2022
- 2022-01-27 IL IL290166A patent/IL290166A/en unknown
-
2023
- 2023-02-15 US US18/169,368 patent/US20230414698A1/en active Pending
- 2023-10-02 JP JP2023171324A patent/JP2023166014A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3394095B1 (en) | 2023-09-27 |
US20200316158A1 (en) | 2020-10-08 |
CN108463470B (en) | 2021-10-22 |
WO2017112757A1 (en) | 2017-06-29 |
JP2021185201A (en) | 2021-12-09 |
JP6943858B2 (en) | 2021-10-06 |
IL290166A (en) | 2022-03-01 |
US10695395B2 (en) | 2020-06-30 |
CA3006998A1 (en) | 2017-06-29 |
IL259583B (en) | 2022-03-01 |
EP3394095A1 (en) | 2018-10-31 |
EP3394095A4 (en) | 2019-08-14 |
MX2018007468A (en) | 2018-11-14 |
CN108463470A (en) | 2018-08-28 |
JP2019504043A (en) | 2019-02-14 |
JP2023166014A (en) | 2023-11-17 |
US20190000912A1 (en) | 2019-01-03 |
CN114225013A (en) | 2022-03-25 |
IL259583A (en) | 2018-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230414698A1 (en) | Collagen 7 compositions and methods of using the same | |
JP7159277B2 (en) | Rapid-acting insulin composition | |
US11633462B2 (en) | Pharmaceutical composition comprising plasminogen and uses thereof | |
CN106456717B (en) | Quick-acting insulin composition | |
KR102579789B1 (en) | C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency | |
JP6525987B2 (en) | Stable preparation of insulin glulysin | |
US20150150982A1 (en) | Pharmaceutical formulation for a therapeutic antibody | |
JP2010513462A (en) | Factor VII and Factor VIIa compositions | |
US20210070852A1 (en) | Anti-IL-23p19 Antibody Formulations | |
JP2003504346A (en) | Growth hormone preparations | |
JP6869255B2 (en) | Frozen pharmaceutical product and its use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: PHOENIX TISSUE REPAIR, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SHIRE HUMAN GENETICS THERAPIES, INC.;REEL/FRAME:065402/0109 Effective date: 20170721 Owner name: SHIRE HUMAN GENETIC THERAPIES, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:QUINONES-GARCIA, IGOR;GUEY, LIN;LOWE, KRIS;AND OTHERS;SIGNING DATES FROM 20170101 TO 20170116;REEL/FRAME:065412/0491 |
|
AS | Assignment |
Owner name: BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT, NEW YORK Free format text: SECURITY INTEREST;ASSIGNORS:CALCILYTIX THERAPEUTICS INC.;ADRENAS THERAPEUTICS INC.;PHOENIX TISSUE REPAIR, INC.;AND OTHERS;REEL/FRAME:066342/0154 Effective date: 20240117 |
|
AS | Assignment |
Owner name: BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT, NEW YORK Free format text: SECURITY INTEREST;ASSIGNORS:BRIDGEBIO PHARMA, INC.;QED THERAPEUTICS, INC.;EIDOS THERAPEUTICS, INC.;AND OTHERS;REEL/FRAME:066355/0126 Effective date: 20240117 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |